Gianfranco Nazzi – CEO, Almirall
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.[4]
In 2016, it generated a total revenue of 859.3 million € [5] and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and the United States.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Invest in Catalonia discuss the Spanish region’s track record when it comes to the pharmaceutical and biotech sectors, where investment is going today in the region, and the factors that…
Walther von Plettenberg, general manager of the German-Spanish Chamber of Commerce in Spain, traces the history of the organization’s activity and highlights the efforts of the Chamber in response to…
Since PharmaBoardroom interviewed Juan López-Belmonte, CEO of Rovi, in 2008, the market has changed drastically. López-Belmonte outlines some of those changes and how Rovi has successfully adapted, having achieved significant…
Emilio Lora-Tamayo, president of the Spanish National Research Council (CSIC), outlines Spain’s current strengths and weaknesses in the areas of research and innovation. Could you please introduce yourself to our…
Despite a number of setbacks in public funding as a result of Spain’s recession, the Spanish National Biotechnology Center (CNB) has continued to remain at the forefront of science and…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
José Fernández, president of the Zeltia Group, outlines the company’s strategy for developing oncology drugs through marine-based organisms with the group’s subsidiary PharmaMar. With €550 [SG1] million invested in research and…
The history of AmCham Spain dates back to 1917 and has a critical part of developing bilateral relations between Spain and the United States. The company’s president, Jaime Malet, discusses…
Baxter Spain’s general manager, Luigi Antoniazzi, discusses the challenges that the affiliate has faced in light of recent changes in the market, and the strategies taken to adapt to an…
Spain’s pharmaceutical industry has been under a lot of pressure in the past few years: public expenditure on pharmaceuticals contracted nearly 29 percent between May 2010 and December 2013. Numerous…
Bernardo de Rafael Topfer, Iberia Country Manager, speaks about how middle-sized companies like Orion can use niche indications to their advantage in the face of strong competition from big pharma’s…
See our Cookie Privacy Policy Here
